Souzan Sanati MD
Cytopathology, Anatomic Pathology, Clinical Pathology, Surgical Pathology
Assistant Professor, Pathology & Immunology, Washington University School of Medicine
Join to view full profile
8700 Beverly Blvd# SB290West Hollywood, CA 90048
Phone+1 310-248-6240
Fax+1 310-439-1906
Dr. Sanati is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterFellowship, Gynecologic Pathology, 2008 - 2009
Washington University/B-JH/SLCH ConsortiumFellowship, Cytopathology, 2006 - 2007- Washington University/B-JH/SLCH Consortium Gynecologic and Breast PathologyFellowship, Selective Pathology, 2005 - 2006
University of Texas Medical Branch HospitalsResidency, Pathology-Anatomic and Clinical, 2001 - 2005
Iran University of Medical SciencesClass of 1993
Certifications & Licensure
CA State Medical License 2015 - 2027
IL State Medical License 2016 - 2020
MO State Medical License 2007 - 2020
American Board of Pathology Pathology - Anatomic/Pathology - Clinical- American Board of Pathology Cytopathology
Clinical Trials
- PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Start of enrollment: 2013 Apr 10
- Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer
- Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer Start of enrollment: 2014 Apr 02
Publications & Presentations
PubMed
- Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.Tim Kong, Alex Mabry, Maureen Highkin, Anthony Z Wang, Jeremy Hoog
Nature Communications. 2026-01-27 - 2 citationsAnalytical Comparison of Commonly Used Laboratory-Developed Tests for the Assessment of Ki-67 in Breast Carcinoma With a Food and Drug Administration-Approved Benchmark.Sunil Badve, Jason S White, Francisco Sapunar, Kelli Thoele, Sameera R Wijayawardana
Modern Pathology. 2025-10-01 - 16 citationsEndocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or...Cynthia X Ma, Vera J Suman, Souzan Sanati, Kiran Vij, Meenakshi Anurag
JAMA Oncology. 2024-03-01
Journal Articles
- Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer XenograftsSouzan Sanati, Jana W Qiao, Xian Chen, Matthew J Ellis, Cynthia Ma, Nature
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
